Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dazodalibep
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Dazodalibep is an investigational recombinant fusion protein designed as a CD40 ligand (CD40L, also known as CD154) antagonist. It blocks the interaction between T cells and CD40-expressing B cells, thereby disrupting the overactivation of the CD40-CD40L co-stimulatory pathway that is implicated in several autoimmune diseases. Dazodalibep is being developed primarily for Sjögren's syndrome, where it has shown efficacy in reducing systemic disease activity and improving symptoms such as dryness and fatigue in clinical trials. The drug was originally developed by MedImmune and Viela Bio, later acquired by Horizon Therapeutics, with current development led by Amgen[1][2][5].
- Other names
- dazodalibep
02
Targets
CD40LG (CD40 ligand extracellular domain)
Beyond the preview
Go deeper on dazodalibep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dazodalibep.